379. Clinical background and course of non-pylori Helicobacter bacteremia in Japan
Session: Poster Abstract Session: Epidemiology - Bacterial Infections
Friday, October 21, 2011
Room: Poster Hall B1
  • IDSA poster presentation (No. 379 Akihiro Inui).pdf (3.5 MB)
  • Background: Several non-pylori Helicobacter species are known to cause infections in humans. Bacteremia caused by these species in immunocompromised patients, such as patients infected with human immunodeficiency virus (HIV), has been previously reported. We analyzed the clinical backgrounds and courses of non-pylori Helicobacter bacteremia patients to investigate the risk factors involved and adequate treatment.

    Methods: We conducted a 17-year retrospective chart review of non-pylori bacteremia at Juntendo University Hospital between 1994 and 2010. The species of non-pylori Helicobacter detected in clinical isolates were identified by 16S ribosomal DNA sequencing. Antimicrobial susceptibility testing was carried out using the disk diffusion method.

    Results: Of the 4,261 bacteremia patients examined, six patients had bacteremia due to non-pylori Helicobacter: two had blood dyscrasia while receiving anticancer therapy, one had renal disease on hemodialysis, one had collagenous disease under treatment with steroids and the final two were immunocompetent hosts. Three isolates were identified as Helicobacter cinaedi and one was identified as Helicobacter fennelliae. All isolates showed resistance to erythromycin, clindamycin, nalidixic acid, and levofloxacin. Of the six non-pylori Helicobacter patients, four were treated with beta-lactam antimicrobials and two were treated without antimicrobials. All patients were successfully cured.

    Conclusion: Immunocompromised hosts appear to be at risk for non-pylori Helicobacter bacteremia. There is the possibility, however, that non-pylori Helicobacter bacteremia can also occur in immunocompetent hosts. This retrospective analysis suggests that beta-lactam antimicrobials are a good first choice for non-pylori infections.

    Subject Category: C. Clinical studies of bacterial infections and antibacterials including sexually transmitted diseases and mycobacterial infections (surveys, epidemiology, and clinical trials)

    Akihiro Inui, MD1, Yuki Uehara, MD2, Hiromizu Takahashi, MD1, Toshio Naito, MD1, Shigeki Misawa, MT3, Ken Kikuchi, MD4 and Hiroshi Isonuma, MD1, (1)Department of General Medicine, Juntendo University School of Medicine, Tokyo, Japan, (2)Department of General Medicine/Infection Control Science, Juntendo University Faculty of Medicine, Tokyo, Japan, (3)Department of Clinical Laboratory, Juntendo University School of Medicine, Tokyo, Japan, (4)Department of Infectious Control Science, Juntendo University Faculty of Medicine, Tokyo, Japan


    A. Inui, None

    Y. Uehara, None

    H. Takahashi, None

    T. Naito, None

    S. Misawa, None

    K. Kikuchi, None

    H. Isonuma, None

    Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.